Document is current
Any future updates will be listed below
-
Authors
Greiser, Julia
Engert, Beatrice
Föll, Roman
Klopfleisch, Robert
Steens, Rebecca
Hecht, Marion
Freesmeyer, Martin https://orcid.org/0000-0002-6462-3851
-
Funding
Funding for this research was provided by:
Interdisciplinary Centre for Clinical Research, Jena University Hospital (MSP15)
Friedrich-Schiller-Universität Jena (FKZ Talent/2023-06-01)
Universitätsklinikum Jena
- License Information
-
More Information
Article History
Received: 12 March 2025
Accepted: 16 April 2025
First Online: 17 May 2025
Declarations
:
: All animal experiments were carried out under a protocol approved by the institutional ethics commitee of vivo Science and authorized by the State Agency for Nature, Environment and Consumer Protection (Landesamt für Natur, Umwelt und Verbraucherschutz; LANUV, no. 81-02.04.40.2023.VG016/001). The study was conducted in accordance with the ARRIVE guidelines and in accordance with the European directives on the protection and use of animals used for scientific purposes (Council Directive 2010/63/EU) and the European Convention for the Protection of Vertebrate Animals used for Experimental and Other Scientific Purposes of the Council of Europe (Directive ETS No. 123, 1986, Appendix A (2006)).
: Not applicable.
: Julia Greiser and Martin Freesmeyer are the inventors of the patented test item (WO2019115429 A1). This patent is owned by x-nuclear Diagnostics GmbH. inflamed pharma GmbH (employee Beatrice Engert) holds a patent pending on the solubilized formulation of the test item. Vivo Science GmbH (employees Marion Hecht and Rebecca Steens) was paid by inflamed pharma GmbH for carrying out the study. Roman Föll and Robert Klopfleisch acted as consultants for study design and implementation and were paid for this service by inflamed pharma GmbH.
